Clinical trial
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With…
NCT00139919 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00139919 |
|---|---|
| Title | Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study of the Safety and Tolerability of Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Either Schizophrenia or Bipolar Disorder With an Optional Open-Label 26-Week Extension Study |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Collaborators | H. Lundbeck A/S Industry Wyeth is now a wholly owned subsidiary of Pfizer |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Bifeprunox |
| Start date | Jan 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Aug 31, 2005 |
| Last update posted | Jan 16, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: